Application of Quantitative Indexes of FDG PET to Treatment Response Evaluation in Indolent Lymphoma
Although 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a standard imaging modality for response evaluation in FDG-avid lymphoma, there is a controversy using FDG PET in indolent lymphoma. The purpose of this study was to investigate the effectiveness of quantitative indexes on FDG PET in response evaluation of the indolent lymphoma.
Fifty-seven indolent lymphoma patients who completed chemotherapy were retrospectively enrolled. FDG PET/computed tomography (CT) scans were performed at baseline, interim, and end of treatment (EOT). Response was determined by Lugano classification, and progression-free survival (PFS) by follow-up data. Maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured in the single hottest lesion (target A) or five hottest lesions (target B). Their efficacies regarding response evaluation and PFS prediction were evaluated.
On EOT PET, SUVmax, and MTV of both targets were well associated with visual analysis. Changes between initial and EOT PET were not significantly different between CR and non-CR groups. On interim PET, SUVmax, and %ΔSUVmax in both targets were significantly different between CR and non-CR groups. For prediction of PFS, most tested indexes were significant on EOT and interim PET, with SUVmax being the most significant prognostic factor.
Quantitative indexes of FDG PET are well associated with Lugano classification in indolent lymphoma. SUVmax measured in the single hottest lesion can be effective in response evaluation and prognosis prediction on interim and EOT PET.
KeywordsIndolent lymphoma 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) Response evaluation
Compliance with Ethical Standards
Conflict of Interest
Hyun Joo Kim, Reeree Lee, Hongyoon Choi, Jin Chul Paeng, Gi Jeong Cheon, Dong Soo Lee, June-Key Chung, and Keon Wook Kang declare that they have no conflict of interest.
All procedures followed were performed in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2013.
The study design of the retrospective analysis and exemption of informed consent were approved by the Institutional Review Board of the Seoul National University Hospital (H-1703-108-840). This manuscript has not been published before or is not under consideration for publication anywhere else and has been approved by all co-authors.
- 8.Ciobanu A, Stanca O, Triantafyllidis I, Lupu A. Indolent lymphoma: diagnosis and prognosis in medical practice. Maedica (Buchar). 2013;8:338–42.Google Scholar
- 15.Hosein PJ, Lossos IS. The evolving role of F-FDG PET scans in patients with aggressive non-Hodgkin’s lymphoma. Eur J Clin Med Oncol. 2010;2:131–8.Google Scholar
- 25.Esfahani SA, Heidari P, Halpern EF, Hochberg EP, Palmer EL, Mahmood U. Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. Am J Nucl Med Mol Imaging. 2013;3:272–81.PubMedPubMedCentralGoogle Scholar
- 27.Cheson BD, Kostakoglu L. FDG-PET for early response assessment in lymphomas. Part 1—Hodgkin lymphoma. Oncology (Williston Park). 2017;31:45–9.Google Scholar
- 31.Cheson BD, Kostakoglu L. FDG-PET for early response assessment in lymphomas. Part 2—diffuse large B-cell lymphoma, Use of Quantitative PET Evaluation. Oncology (Williston Park). 2017;31:71–6.Google Scholar